



<http://www.endocyte.com>

October 13, 2008

NEWS RELEASE

Endocyte to Present at the BIO Investor Forum 2008

WEST LAFAYETTE, Ind. – October 13, 2008 – Endocyte, Inc. announced today that Ron Ellis, President and CEO of Endocyte, Inc., will present at the BIO Investor Forum 2008 on Wednesday, October 29, 2008 at 3:15 PM at the Palace Hotel in San Francisco, California.

Mr. Ellis's presentation will provide an update on Endocyte's development efforts in the areas of oncology and inflammatory diseases and clinical trials.

About Endocyte, Inc.

Endocyte, Inc., located at the Purdue Research Park in West Lafayette, Ind., uses an advanced targeting technology that makes it possible to develop custom guidance systems for drugs. The technology is designed to make drugs more effective by targeting them directly to receptors found on diseased cells. With improved targeting, Endocyte plans to develop new therapies using proven powerful drugs that are currently not widely used due to dose limiting toxicities. With the increased specificity afforded by Endocyte's patented technology, these drugs could be dosed for maximum efficacy, but with a significant reduction in side effects.

Endocyte is currently testing four agents in clinical trials: EC20, a targeted diagnostic imaging agent used to identify patients likely to respond to the therapy; EC145, a targeted chemotherapeutic agent in phase 2 studies for patients with advanced ovarian and non small cell lung cancers, as well as a phase 2b study for patients with platinum resistant ovarian cancer; EC17, a targeted immunotherapy in a phase 1b study of advanced kidney cancer; and EC0225, a chemotherapeutic agent targeting two drugs currently in a phase 1 clinical study. In addition, Endocyte has established a collaborative development program with Bristol-Myers Squibb.

For further information, visit <http://www.endocyte.com>.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties that may cause results to differ materially from those set forth in the statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contacts:

Vickey Buskirk, media relations, Endocyte Inc., (765) 463-7175 ext. 1117, vbuskirk@endocyte.com

###